Skip to content

Comparison of the effect of two progesteron drugs in protection of abortion

Comparison of Vaginal Progesterone and Oral Micronized Progesterone on Pregnancy Outcomes in Women with Threatened Miscarriage

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120104008611N9
Enrollment
160
Registered
2019-05-12
Start date
2018-04-21
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion. -

Interventions

Intervention 1: Intervention group: Progesterone suppository 400 milligrams per day. Intervention 2: Intervention group: Progesterone capsule 100 mg per day.

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Gestational age 6 to 13 weeks Apearance of fetal heart rate Uterine bleeding Closed uterine orifice

Exclusion criteria

Exclusion criteria: Having embryonic or uterine anomalies in ultrasound Multi fetal Hydatidiform mole A known underlying disease in mother Patients who have been treated by a specific medication to treat abortion the absence of fetal heartbeat, malignancy presence of anorectal disorders genital tract infections endocrine disorders cardiovascular disorders progesterone hypersensitivity refusal to participate

Design outcomes

Primary

MeasureTime frame
Abortion. Timepoint: From the start of the intervention up to end of pregnancy. Method of measurement: Weekly visit until the end of bleeding.

Secondary

MeasureTime frame
Preeclampsia. Timepoint: Up to 28 weeks monthly until 36 weeks every two weeks and thereafter weekly until delivery. Method of measurement: Mercury pressure gauge.;Gestational Diabetes. Timepoint: Up to 28 weeks monthly until 36 weeks every two weeks and thereafter weekly until delivery. Method of measurement: Glucose tolerance test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hamideh Pakniat

Qazvin University of Medical Sciences

pakniat110@yahoo.com+98 28 3223 6374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026